Pediatric Hematology, Oncology and Bone Marrow Transplant
Conditions and Treatments

Pediatric Hematology, Oncology and Bone Marrow Transplant

Conditions and Treatments

Comprehensive care within the American Family Children's Hospital Pediatric Hematology, Oncology and Bone Marrow Transplant program means having the ability to readily access the knowledge and skills of many medical and supportive care specialists in the coordinated care of patients with a complex health diagnoses like cancer.

Search for clinical trials available at the UW Carbone Cancer Center

Cancer Immunotherapy Clinical Trials

Mario Otto, MD, PhD is offering an innovative haploidentical stem cell transplant approach using alpha-beta T cell depletion and NK cell mismatch for children with refractory hematologic malignancies (leukemia and lymphoma) and solid tumors (neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma). We are the only center in the country using Zoledronate to expand gamma-delta T cells, and the only center treating children with refractory solid tumors with this approach. Learn more.

A promising new treatment, known as chimeric antigen receptor or CAR T-cell therapy, is now available at American Family Children’s Hospital for children with acute lymphoblastic leukemia (ALL) that either did not respond to standard therapy or has relapsed a second time. Christian Capitini, MD, is the site PI for this study.

Ken DeSantes, MD leads a unique clinical trial only available at AFCH, involving infusion of haploidentical (from a parent) natural killer cells with an immunocytokine for children with relapsed or refractory neuroblastoma. The immunocytokine targets GD2, a sugar found on neuroblastoma, and activates immune cells with interleukin-2.

Targeted Radiotherapy Treatments

This radionuclide therapy is offered to patients with neuroblastoma, paraganglioma or pheochromocytoma that have either relapsed or have not responded to treatment. This is an open label, expanded access protocol trial, led by Kenneth DeSantes, MD, site PI.

This is an open label, phase 1, dose escalation study with the broadly tumor targeted radiopharmaceutical, CLR 131, led by Mario Otto, MD, PhD. CLR 131 is a small molecule radiopharmaceutical that delivers tumor-killing radioactive iodine-131 to tumors regardless of location in the body. The goal of the study is to test safety and feasibility and determine the recommended clinical phase 2 dosing regimen.

Treatments for Hematologic and Oncologic Diagnoses

Related Services for Pediatric Hematology and Oncology Patients

Multidisciplinary Pediatric Hematology and Oncology Clinics

Multidisciplinary comprehensive clinics are held for the treatment of certain disorders. Oncologists, hematologists, nurse specialists, social workers, physical therapists and geneticists work together with patients, family members and primary care providers to develop a plan for care for children who have specialized needs due to their conditions.

At American Family Children's Hospital, the sub-specialty clinics include: